“…Against this backdrop, low-dose sirolimus seems to be as efficacious as conventional dose sirolimus in patients with LAM, albeit at a risk of lower efficacy but with a lower frequency of AEs. Unfortunately, the design of adequately powered pivotal trials is challenging in rare diseases, for example, only few case reports exist in Indian literature regarding LAM,[212223] and the largest Indian registry of interstitial lung disease, ILD India Registry, mentioned LAM in only 2 (0.2%) of 1047 cases. [24] Such data call for multicentric and multinational studies from densely populated countries such as India and China with a uniform protocol of diagnosis and treatment which might offer the opportunity to have adequate numbers for robust statistical conclusions on the management of such diseases.…”